Organon & Co. (OGN) Stock Forecast & Price Target
Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 13, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Organon & Co. (OGN), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Organon & Co., analysts forecast revenue rising from $6.22B in 2025 to $6.50B in 2030; the average estimate for 2030 earnings per share is $3.90; with published estimates ranging from $3.84 to $3.97; 6 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Organon & Co. (OGN) forecast — frequently asked questions
What is the analyst price target for Organon & Co.?
Analysts covering Organon & Co. (OGN) have a consensus price target of $11.33, 18.5% below the current price of $13.90. Published targets range from $8.00 to $14.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Organon & Co.'s earnings?
The average analyst estimate for Organon & Co. (OGN) earnings per share in 2030 is 3.90, with individual estimates between 3.84 and 3.97.
How much revenue is Organon & Co. expected to make?
Analysts forecast Organon & Co. (OGN) revenue of $6.50B in 2030, based on 2 published estimates.
How many analysts cover OGN?
6 analysts contribute estimates for Organon & Co. (OGN). Thin coverage makes an average less reliable.
Analyst forecasts for other Drug Manufacturers - General stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.